<DOC>
	<DOCNO>NCT01408095</DOCNO>
	<brief_summary>The study design see daily oral dosing LY2608204 help control diabetes measure glycosylated fraction hemoglobin A ( HbA1c ) level . It also help determine safety medication useful dose medication .</brief_summary>
	<brief_title>A Study Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Clinical diagnosis type 2 diabetes mellitus prior enter trial May treat : 1 . Diet exercise alone 2 . Diet exercise combination stable dose metformin least 3 month Screening 3 . Diet exercise combination stable dose sulfonylurea meglitinide ( repaglinide , nateglinide ) least 3 month Screening 4 . Diet exercise combination stable dos metformin sulfonylurea metformin meglitinides least 3 month Screening diabetes least 6 year Must Hemoglobin A1c value 7 % 10 % Must body mass index ( BMI ) 20 40 kg/m2 Must stable weight 3 month prior Screening ( weight change exceed 5 kg ( 11 lb ) ) If female , must able get pregnant Must well motivate , capable , willing complete study require glucose monitoring instruction Use insulin antidiabetic agent metformin sulfonylurea meglitinide 3 month prior Screening Have gastrointestinal disease significantly impact gastric empty motility undergone gastric bypass gastric band surgery Have one episode severe hypoglycemia within 6 month prior entry study , currently diagnose hypoglycemia unawareness 2 emergency room visit hospitalization due poor glucose control past 6 month Are currently take take within last 2 month , prescription overthe counter medication affect body weight Have cardiac disease functional status New York Heart Association [ NYHA ] Class II , III , IV history myocardial infarction , unstable angina , decompensated congestive heart failure past 6 month . Have poorly control hypertension , history malignant hypertension , evidence renal artery stenosis and/or evidence labile blood pressure include symptomatic postural hypotension . Doses antihypertensive medication must stable 30 day randomization Have QTcB ( Bazett'scorrected QT interval ) interval great 450 msec men great 470 woman Screening personal history ventricular tachycardia unexplained syncope Have obvious clinical sign symptom liver disease , acute chronic hepatitis , significantly elevate liver blood test Are currently receive renal dialysis , serum creatinine great 2.0 mg/dL ( 177 Î¼mol/L ) calculate creatinine clearance le 60 ml/min patient treat metformin , know contradiction metformin use include , limited , serum creatinine ( creatinine clearance ) approve metformin product label Have fast state hypertriglyceridemia ( define great 5.65 mmol/L , 500 mg/dl ) Screening . If take lipidlowering agent , dos medication must stable 30 day prior randomization . Are receive chronic ( 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 4 week immediately prior Randomization Have active untreated malignancy remission clinically significant malignancy ( basal squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year Have history seizure disorder Are currently use intend use inhibitor Cytochrome P450 family 3A ( CYP3A4 ) Currently take medication sensitive substrate CYP3A4 pathway narrow therapeutic index</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>glimepiride</keyword>
	<keyword>diabetes type II</keyword>
	<keyword>diabetes type 2</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>